Motexafin gadolinium
| Motexafin gadolinium | |
|---|---|
| Motexafin_gadolinium_3D_sticks.png | |
| INN | |
| Drug class | |
| Routes of administration | Intravenous |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | Investigational |
| CAS Number | 156436-89-4 |
| PubChem | 3081363 |
| DrugBank | DB04910 |
| ChemSpider | 2338659 |
| KEGG | D05102 |
Motexafin gadolinium is a pharmaceutical compound that has been investigated for its potential use in the treatment of cancer. It is a member of a class of drugs known as texaphyrins, which are synthetic porphyrin-like molecules. Motexafin gadolinium is notable for its ability to selectively accumulate in cancer cells and disrupt their metabolism, making it a promising agent for radiation therapy and chemotherapy.
Mechanism of Action[edit]
Motexafin gadolinium works by targeting the redox processes within cancer cells. It is a redox-active drug that can accept and donate electrons, disrupting the normal redox balance within the cell. This disruption leads to the generation of reactive oxygen species (ROS), which can damage cellular components such as DNA, proteins, and lipids. The accumulation of ROS in cancer cells can lead to apoptosis, or programmed cell death.
Clinical Applications[edit]
Motexafin gadolinium has been primarily studied in the context of brain metastases from lung cancer and other solid tumors. It has been used in combination with whole brain radiation therapy (WBRT) to enhance the therapeutic effects of radiation. The drug's ability to selectively accumulate in tumor tissues while sparing normal tissues makes it an attractive candidate for combination therapies.
Research and Development[edit]
Research on motexafin gadolinium has focused on its potential to improve outcomes in patients with brain metastases. Clinical trials have explored its efficacy and safety in combination with radiation therapy. While some studies have shown promising results, further research is needed to fully establish its clinical benefits and potential side effects.
Chemical Properties[edit]
Motexafin gadolinium is a complex molecule with a central gadolinium ion. The gadolinium is coordinated by a large organic ligand, which is responsible for the drug's ability to interact with cellular components. The presence of gadolinium also makes the compound paramagnetic, which has implications for its use in magnetic resonance imaging (MRI).
Safety and Side Effects[edit]
As with many investigational drugs, the safety profile of motexafin gadolinium is still being evaluated. Potential side effects may include fatigue, nausea, and changes in liver function tests. The drug's interaction with radiation therapy may also lead to enhanced side effects, which are being carefully monitored in clinical trials.
